Core Viewpoint - Teladoc (TDOC) is showing potential for short-term gains as it has crossed above the 20-day moving average, indicating a bullish trend [1][4]. Technical Analysis - TDOC has reached a key level of support and has been moving higher over the past four weeks, with an increase of 13.5% [1][4]. - The 20-day simple moving average is a significant indicator for short-term traders, as it smooths out price trends and provides more signals for trend reversals compared to longer-term averages [1][2]. Earnings Estimates - The company currently holds a Zacks Rank 1 (Strong Buy), suggesting a favorable outlook for continued price increases [4]. - In the past two months, no earnings estimates for TDOC have been lowered, while one estimate has been raised, contributing to a positive consensus estimate for the current fiscal year [4][5].

Group 1 - Teladoc (TDOC) has recently reached a key level of support and has overtaken the 200-day moving average, indicating a long-term bullish trend [1] - The stock has moved 13.5% higher over the last four weeks and is currently rated as a Zacks Rank 1 (Strong Buy) [2] - Positive earnings estimate revisions support the bullish outlook, with no estimates decreasing in the past two months and one estimate increasing, leading to a consensus estimate increase [2] Group 2 - Investors are encouraged to monitor TDOC for potential gains due to its key technical level and favorable earnings estimate revisions [3]

Core Insights - Teladoc Health, Inc. has launched a new solution as part of its Clarity monitoring platform, aimed at enhancing workplace safety in healthcare settings by addressing workplace violence [1][4][9] Group 1: New Features and Implementation - The Clarity platform now includes features for virtual intervention to combat workplace violence, initially designed for virtual patient sitting [1][2] - The new workplace safety feature will be rolled out in partnership with selected hospitals and health systems starting in Q1 2026 [2] - The functionality utilizes video and audio analysis to detect threats, sending real-time alerts to care teams for timely intervention [3][9] Group 2: Industry Context and Benefits - Workplace violence is a growing concern in hospitals, impacting staff safety and imposing financial burdens on healthcare institutions [4] - The addition of the new capability is expected to enhance the attractiveness of the Clarity platform, potentially increasing Teladoc Health's revenue as more hospitals adopt the solution [5] Group 3: Company Performance - Teladoc Health's shares have increased by 29.4% over the past six months, significantly outperforming the industry average growth of 1.2% [8]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Investors following momentum investing often avoid undervalued stocks, believing that quicker profits can be made from trending stocks [1] - Identifying the right entry point for fast-moving stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] Group 2: Bargain Stocks with Momentum - Investing in bargain stocks that have recently shown price momentum may be a safer strategy [2] - The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced fast-moving stocks [2] Group 3: Teladoc (TDOC) Analysis - Teladoc (TDOC) has shown a price increase of 13.5% over the past four weeks, indicating growing investor interest [3] - TDOC has gained 6.1% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 1.9, suggesting it moves 90% higher than the market in either direction, indicating fast-paced momentum [4] Group 4: Valuation and Earnings Estimates - TDOC has a Momentum Score of B, suggesting it is a favorable time to invest in the stock [5] - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which typically attract more investors [6] - TDOC is trading at a Price-to-Sales ratio of 0.62, indicating it is relatively cheap, as investors pay only 62 cents for each dollar of sales [6] Group 5: Additional Investment Opportunities - Besides TDOC, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting additional investment opportunities [7] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [8]

Core Insights - Teladoc Health has launched a new capability aimed at addressing workplace violence in healthcare settings, enhancing its Clarity™ monitoring solution with AI-enabled technology [1][4] - Workplace violence is a significant issue in healthcare, with over 80% of nurses reporting experiences of violence and healthcare workers being five times more likely to face such incidents compared to other industries [2][3] - The new solution utilizes video and audio analysis to detect threatening behaviors and provide timely notifications for early intervention, thereby improving safety in care environments [3][4] Industry Context - The prevalence of workplace violence in healthcare is alarming, with nearly half of nurses indicating an increase in violence in recent years [2] - The financial impact of workplace violence on hospitals exceeds $18 billion annually, highlighting the urgent need for effective solutions [2] Company Strategy - The new workforce safety capability is designed to be proactive, moving beyond traditional reactive measures like panic buttons, and aims to empower care teams through AI-driven insights [4] - Implementation of this solution is set to begin in select hospitals and health systems in Q1 2026 as part of Teladoc Health's partner development program [4]

Core Viewpoint - Teladoc (TDOC) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is driven by changes in a company's earnings picture, which significantly influences stock price movements [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Business Improvement Indicators - The rising earnings estimates for Teladoc suggest an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [5][10]. - Over the past three months, the Zacks Consensus Estimate for Teladoc has increased by 7.3%, indicating a positive trend in earnings expectations [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, highlighting their superior earnings estimate revision features [9][10].

Company Overview - Teladoc (TDOC) shares increased by 6.3% to $9.01 in the last trading session, with a notable trading volume, and have gained 11.1% over the past four weeks [1][2] - The price rise was influenced by Citron Research's bullish stance on Teladoc, highlighting strong performance in its chronic care division, Livongo, which saw a 55% year-over-year increase in usage, marking the highest growth since January 2025 [2] Financial Performance - Teladoc is expected to report a quarterly loss of $0.26 per share, reflecting a year-over-year decline of 36.8%, with revenues projected at $625.56 million, down 2.3% from the previous year [3] - The consensus EPS estimate for Teladoc has remained unchanged over the last 30 days, indicating a lack of upward revisions in earnings estimates, which typically correlates with stock price movements [4] Industry Context - Teladoc is part of the Zacks Medical Services industry, where another company, Strata Critical Medical, Inc. (SRTA), also experienced a price increase of 3.4% to $5.41, with a 25.1% return over the past month [4] - Strata Critical Medical's consensus EPS estimate for the upcoming report has remained unchanged at $0, representing a 100% increase from the previous year [5]

Company Performance - Teladoc (TDOC) ended the recent trading session at $8.37, demonstrating a +2.2% change from the preceding day's closing price, outperforming the S&P 500's daily loss of 0.55% [1] - The shares have seen an increase of 6.78% over the last month, surpassing the Medical sector's loss of 0.2% and the S&P 500's gain of 3.64% [1] Earnings Forecast - The upcoming earnings release is forecasted to report an EPS of -$0.26, showcasing a 36.84% downward movement from the corresponding quarter of the prior year [2] - Revenue is expected to be $625.56 million, showing a 2.33% drop compared to the year-ago quarter [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates anticipate earnings of -$1.17 per share and a revenue of $2.52 billion, signifying shifts of +80.07% and -1.82%, respectively, from the last year [3] - Recent changes to analyst estimates indicate the ever-changing nature of near-term business trends, with positive revisions conveying analysts' confidence in business performance and profit potential [3] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a proven track record of outperformance, with 1 stocks returning an average of +25% annually since 1988 [5] - Teladoc currently holds a Zacks Rank of 3 (Hold), with the Medical Services industry ranking in the top 42% of all industries [5] Industry Evaluation - The Zacks Industry Rank evaluates the power of distinct industry groups, showing that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

All right, newly installed Fed Governor Steven Myron is saying he favored a bigger rate cut at the recent FOMC meeting. Here with the latest on this story is our Fed correspondent Jennifer Shawnberger. Jen, good afternoon.miles. New Federal Reserve Governor Steven Myron said he favored a jumbosized rate cut at the central bank's policy meeting earlier this week because he doesn't see any inflation from tariffs and he favors a policy rate that does not restrict the economy nor spur it. Myron telling CNBC in ...

Company Performance - Teladoc's stock closed at $7.49, down 3.97%, underperforming the S&P 500's daily gain of 0.3% [1] - Over the past month, Teladoc shares appreciated by 13.54%, outperforming the Medical sector's gain of 7.07% and the S&P 500's gain of 2.09% [1] Earnings Projections - The upcoming earnings release projects an earnings per share (EPS) of -$0.24, a 26.32% decrease from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is $625.56 million, down 2.33% from the year-ago period [2] Full Year Estimates - For the full year, the Zacks Consensus Estimates project an EPS of -$1.17 and revenue of $2.52 billion, reflecting changes of +80.07% and -1.82% respectively from the preceding year [3] - Recent changes to analyst estimates indicate a shifting business landscape, with positive revisions suggesting optimism about the business outlook [3] Zacks Rank and Industry Position - The Zacks Rank system, which assesses estimate changes, currently ranks Teladoc as 3 (Hold) [5] - The Medical Services industry, part of the Medical sector, holds a Zacks Industry Rank of 146, placing it in the bottom 41% of over 250 industries [6]